account_id none on file
legal_name Caribou Biosciences, Inc.
ticker CRBU
cik 1619856
domain cariboubio.com
linkedin_company_url https://www.linkedin.com/company/caribou-biosciences/
entry_point_account_id none on file
name Caribou Biosciences Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 3 executives 0 family 0
why_nownone on file
callsnone on file
filings
Impairment charges consist of charges related to the strategic pipeline prioritization with workforce and cost reduction initiatives announced on April 24, 2025, and include impairment of our leasehold improvements, right of use assets, and lab equipment.
filing / Aug 13, 2026 / receipt
As a result, we recorded cash severance costs, benefits, and transition support services expenses of $ 1.8 million for each of the three- and six-month periods ended June 30, 2025, which we recorded as research and development expenses or general and administrative expenses in our unaudited condensed consolidated statements of operations and comprehensive loss.
filing / Aug 13, 2026 / receipt
Restructuring Charge Severance and Wind Down Costs On April 24, 2025, we announced the discontinuation of our preclinical research and two clinical programs.
filing / Aug 13, 2026 / receipt
executivesnone on file
familynone on file
upcoming
| 2026-11-11 | earnings call | scheduled | ir |
changesnone on file
mcp_package_hint
slug caribou-biosciences-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$